Cohen Veterans Bioscience, Stanford Brain Performance Center, and Brain Trauma Foundation join forces to advance precision medicine for TBI
NEW YORK, August 9, 2021 / PRNewswire / – Brain research and advocacy group Cohen Veterans Bioscience (CVB), the Stanford Brain Performance Center (SBPC), and the Brain Trauma Foundation (BTF) announced a collaboration aimed at improving treatment recommendations and guidelines for mild Traumas transform brain injury (TBI) (including concussion) and advance the field towards a precision medicine approach. The new collaboration between CVB, SBPC and BTF is the result of their partnership on the Brain Trauma Blueprint, a framework that enables stakeholders from governments, academia, foundations and industry to advance precision diagnostics and treatment of brain trauma through coordinated efforts.
The framework comprises a 12-step process to jointly identify unmet patient needs and related research priorities, describe the state of the art, identify research gaps and barriers, and make recommendations for progress. In addition, the framework provides a call to action for funders and employees from the broader stakeholder community to participate in a transparent and coordinated network.
Combining expertise in data science, patient care and guideline development, the three organizations aim to redefine the classification of mild TBI using evidence-based patient categorization, with the ultimate goal of generating new treatment strategies and guidelines.
“The Stanford Brain Performance Center and the Brain Trauma Foundation have enhanced our understanding of best practices for traumatic brain injury. We are excited to work with you on this collaboration and provide an important opportunity to build on our complementary strengths,” said Magali Haas, PhD, MD, President and CEO of Cohen Veterans Bioscience. “They bring clinical excellence as we deliver expertise in data science and computational modeling. We expect this initiative to catalyze the adoption of best practice guidelines by taking into account the diversity of different patient subpopulations and breaking down the variability observed in mild TBI towards more tailored cases “and individual solutions.”
Promote TBI treatment by working together to generate recommendations and guidelines for mild TBI
The aim of the collaboration between CVB, SBPC and BTF is to generate recommendations and guidelines based on neurobiological subtypes of mild TBI. In the past five years, several expert agreement letters and clinical practice guidelines for TBI have been published, including Concussion Guidelines Step 2: Evidence for Subtype Classification, written by the directors of the SBPC in 2019, among others. The Step 2 Guidelines outlined evidence-based support for five common concussion subtypes and two related disorders based on clinical data and reported the prevalence of each subtype in the patient population with acute mild TBI.
The new collaboration between BTF, CVB and SBPC aims to build on the Step 2 guidelines and add biologically driven evidence for subtype classification, obtained through independent analysis of existing large, deeply phenotypic cohorts across different types of trauma, including those from Military, sports and accidents. The end result will be a step 3 guideline that will further refine mild TBI and make recommendations based on subtype classifications.
The main investigator is Jamshid Ghajar, MD, PhD, FACS, President Emeritus of BTF, Clinical Professor of Neurosurgery at Stanford University Faculty of Medicine and Director of the SBPC. Co-PIs of the project are Angela Lumba-Brown, MD, Associate Professor of Emergency Medicine, and Lee Lancashire, PhD, Chief Information Officer at Cohen Veterans Bioscience.
“A precision medical approach to diagnostic and management strategies for mild TBI supports the heterogeneity and complexity of the individual patient – and offers the opportunity to leverage advances in data science to provide unparalleled personalized care,” said Dr. Angela Lumba-Brown, Co-director of the Stanford Brain Performance Center and vice chairman of Stanford Emergency Medicine.
“The Stanford Brain Performance Center is excited to partner with CVB to uncover the neurobiology of mTBI subtypes using CVB’s data-driven analytics expertise, resulting in innovative diagnostics and targeted treatment options,” said Dr. Ghajar.
Via Cohen Veteran Bioscience
Cohen Veterans Bioscience is a 501 (c) (3) non-profit biomedical research and technology organization committed to promoting brain health through rapid, precision diagnostics and bespoke therapeutics.
Via the Stanford Brain Performance Center
The Stanford Brain Performance Center is an interdisciplinary center of the Stanford school of medicine. Its mission is to advance the neuroscience of brain performance in development, injury and aging.
About the Brain Trauma Foundation
1986 by Dr. Ghajar, the Brain Trauma Foundation was created to improve the outcome of TBI. BTF develops and maintains the evidence-based TBI guidelines that are now the standard of care for US and international trauma centers and result in a 45% decrease in deaths.
About the brain trauma blueprint
The Brain Trauma Blueprint is a framework for advancing precision diagnostics and therapy for brain trauma through a process of consensus roadmapping of community stakeholders and collaborative execution. Further information can be found at www.braintraumablueprint.org (https://www.braintraumablueprint.org)
Senior Director, Communications
View original content: https://www.prnewswire.com/news-releases/cohen-veterans-bioscience-stanford-brain-performance-center-and-brain-trauma-foundation-join-forces-to-advance-precision- Medizin -for-tbi-301350404.html
SOURCE Cohen Veterans Bioscience